Skip to main content
. 2017 Mar 6;73(6):689–698. doi: 10.1007/s00228-017-2226-2

Table 2.

Pharmacokinetic parameters for BMS-986142 after (a) single-dose administration and (b) at steady state after multiple-dose administration

a. SAD, day 1
BMS-986142 treatment dose Cmax (ng/mL) geometric mean (%CV) Tmax (h) median (min, max) AUC(0-T) (ng h/mL) geometric mean (%CV) AUC(inf) (ng h/mL) geometric mean (%CV) T1/2 (h) mean (SD)
5 mg, n = 6 9.03 (37) 2.03 (1.00, 4.00) 83.1 (51) 102 (52)a 6.87 (3.35)a
15 mg, n = 6 36.9 (21) 2.00 (1.00, 2.00) 369 (12) 388 (10) 8.02 (1.37)
50 mg, n = 6 185 (38) 1.00 (1.00, 2.05) 1561 (31) 1586 (31) 9.70 (1.65)
100 mg, n = 6 311 (17) 1.50 (1.00, 2.00) 2999 (14) 3019 (14) 10.3 (1.03)
300 mg, n = 6 1081 (25) 1.02 (1.00, 2.00) 11,347 (21) 11,390 (21) 10.6 (1.05)
900 mg, n = 6 1878 (31) 2.00 (1.00, 4.00) 28,026 (32) 28,063 (31) 10.7 (2.01)
b. MAD, day 14
BMS-986142 treatment dose Cmax (ng/mL) geometric mean (%CV) Tmax (h) median (min, max) Cmin (ng/mL) geometric mean (%CV) AUC(TAU) geometric mean (%CV) AI_AUC geometric mean (%CV) T1/2 (h) mean (SD)
25 mg, n = 6 56.0 (25) 2.00 (2.00, 4.00) 7.85 (42) 539 (34) 1.57 (22) 10.9 (1.8)
75 mg, n = 6 281 (34) 2.00 (1.00, 2.00) 27.9 (77) 2471 (44) 1.23 (31) 10.7 (1.6)
200 mg, n = 6 592 (37) 2.00 (1.00, 2.00) 67.6 (63) 5527 (41) 1.23 (40) 11.0 (4.6)
350 mg, n = 6 1024 (14) 1.50 (1.00, 2.00) 166 (41) 10,715 (26) 0.984 (32) 10.2 (0.9)

AI_AUC AUC accumulation index, AUC (0-T) area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration, AUC (inf) area under the plasma concentration-time curve from time zero extrapolated to infinite time, AUC (TAU) area under the plasma concentration-time curve in one dosing interval, C max maximum observed plasma concentration, C min minimum observed plasma concentration, MAD multiple ascending dose, SAD single ascending dose, T 1/2 terminal plasma half-life, SD standard deviation, T max time to maximum observed plasma concentration

a n = 5